An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Figure 2

Forest plot of serious adverse events compared between PCSK9 inhibitors and control treatment (placebo or ezetimibe). ^a Treatment with evolocumab Q2W; ^b Treatment with evolocumab Q4W; ^c Treatment with alirocumab Q2W; ^d Treatment with alirocumab Q4W.